Back to School: How biopharma can reboot drug development. Access exclusive analysis here

INKP-102: Phase II completed enrollment

INKP completed enrollment of 210 patients in an investigator-blinded

Read the full 91 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE